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Introduction

55
Lowering blood pressure (BP) in patients with hypertension reduces the risk of cardiovascular events 56 and death, 1,2 but the optimal target BP remains unresolved. [3] [4] [5] [6] Randomised trials failed to demonstrate 57 a benefit of targets <140/90 mmHg, 7,8 and post-hoc analyses have suggested that the benefit of BP-58 lowering treatment might even be reversed below a certain threshold, 5, [9] [10] [11] [12] [13] [14] [15] [16] the so-called "J-curve Interactions between average systolic or diastolic BP and the covariates age (>75 vs ≤75 145 years), diabetes, history of stroke or transient ischaemic attack, heart failure, previous coronary 146 revascularisation, and chronic kidney disease (defined by an estimated glomerular filtration rate
147
[eGFR] <60 mL/min/1·73 m 2 ) at baseline were tested. Subgroup analyses were performed when 148 interactions were significant even after adjustment on the same variables as for the Cox proportional 149 hazards model (model 2).
150
The statistical analysis was performed using SAS (version 9.2, Cary, NC, USA), and the 151 restricted cubic splines were obtained using a SAS macro. 21 
153
Role of the funding source
154
The CLARIFY registry is supported by Servier. The sponsor had no role in the study design or in data 155 analysis, and interpretation; or in the decision to submit the manuscript for publication, but assisted 156 with the set-up, data collection and management of the study in each country. The corresponding 157 author had full access to all the data in the study and had final responsibility for the decision to submit 158 for publication.
160
Results
161
A total of 22,672 adult patients with CAD and hypertension were included in the analysis.
162
Demographic data and baseline characteristics of the patients, overall and for each 10-mmHg-163 increment BP subgroup, are given in Tables 1 and 2 ; baseline medications are indicated in Table S1 164 of the supplementary appendix. Mean age at baseline was 65·2 years (SD 10·0), 17,019 (75%) 165 patients were men, and 15,190 (67%) were white. Compared to patients with high systolic BP, those 166 with a lower systolic BP tended to be younger, leaner, more likely to be men, without diabetes, and 167 current smokers, with a higher baseline incidence of myocardial infarction and percutaneous coronary 168 intervention, a lower prevalence of stroke, and lower baseline high-density and low-density lipoprotein 169 cholesterol levels. Patients with lower diastolic BP tended to be older, leaner, more likely to be women, 170 diabetic, and non-smokers, with lower baseline levels of low-density lipoprotein cholesterol. Mean 171 average systolic and diastolic BPs were 133·7 (SD 16·7) and 78·2 mmHg (SD 10·1), respectively.
7 After a median follow-up of 5·0 years (interquartile range 4·5-5·1), 2101 patients (9·3%) met 175 the primary composite outcome. Cardiovascular death, all-cause death, myocardial infarction (fatal or 176 not), stroke (fatal or not), and hospitalisation for heart failure occurred in 1209 (5·3%), 1890 (8·3%), 177 827 (3·6%), 526 (2·3%), and 1306 (5·8%) patients, respectively.
178
Crude and adjusted HRs for average systolic and diastolic BP subgroups are given in Table 3 
200
results were observed in a sensitivity analysis excluding patients with heart failure at baseline (Table   201 3), and similar trends were obtained when using baseline BP and last BP before an event or during differences among the BP groups in their association with outcome was slightly attenuated with 205 increasing time. However this does not change the overall interpretation of the results.
206
Interaction analyses are presented in Table S3 
215
the increased risk at low BP was only significant for diastolic BP <60 mmHg in patients >75 years,
216
whereas it was significant as early as 70 mmHg in the younger patients ( 
225
Our results are consistent with previous post-hoc analyses from randomised trials in patients 226 with hypertension and CAD. 10, 12, 19 Likewise, a J-curve (i.e. an increase in risk of cardiovascular events 227 below a certain BP level) has also been described in other high-risk populations, such as patients with 228 a previous cardiovascular event, or diabetes with target organ damage. 14, 15 However, our study was 229 based on a large cohort from routine practice with no predefined BP intervention, which may confound 230 the analysis: any retrospective analysis of a BP-intervention trial will carry the bias of baseline BP, 231 which will differ between the groups defined by BP achieved during the trial. Additionally, the J-curve Previous observational studies have yielded conflicting results regarding the risk of stroke,
234
which was J-shaped with systolic BP in the post-hoc analysis of patients with previous stroke from the 235 PRoFESS trial 22 and was unaffected by the large decrease in systolic BP in the SPRINT trial, 18 but 236 decreased with decreasing diastolic or systolic BP with no evidence of a J-curve inflection in other 237 trials. [10] [11] [12] 15 In our study, neither a low diastolic nor a low systolic BP was associated with increased 238 risk of stroke, in contrast with high systolic or diastolic BP, and no interaction between BP and 239 previous stroke was evidenced. The number of patients with a stroke was, however, smaller than that 240 for other endpoints.
241
In the debate about the J-curve concept, there is a concern for "reverse causality" (i.e. a low 242 systolic or diastolic BP may only be a marker of poor health rather than the cause of worse clinical 243 outcomes 
257
A particular strength of our study is that it includes a large international cohort of patients, 258 treated in "real-life" conditions. Results from this broad representative cohort may have greater 259 external validity than the highly selected populations from randomised trials. 24 There is a concern that 260 low BP goals from randomised trials, when translated into routine practice, may be associated with 261 higher adverse effects or worse outcomes, especially in older patients. 3, 25 In light of discrepant results of tight BP control trials in patients with diabetes 7 or stroke 8 versus 263 neither of these conditions, 18 we examined interactions between BP lowering and these conditions and 264 found none, which is consistent with previous observations. 10,12,15 However, we found an interaction 265 between both systolic and diastolic BP and age. Interestingly, the J-curve for systolic BP was shifted to 266 the right in patients >75 years, which is in agreement with international guidelines, which advocate for 267 a higher target systolic BP of 150 mmHg in older patients. 26 
268
The SPRINT trial and a recent meta-analysis appeared to argue against a J-curve 269 phenomenon. 
Fasting triglycerides (mmol/L) 16,806
Data are n (%) for categorical data and mean (SD) or median (IQR) for continuous data, depending on the distribution of the data.
Some percentages do not add up to 100 because of rounding· BP=blood pressure. NYHA=New York Heart Association Functional Classification. HDL-cholesterol=high-density lipoprotein cholesterol. LDL-cholesterol= low-density lipoprotein cholesterol.
. 
Data are n (%) for categorical data and mean (SD) or median (IQR) for continuous data, depending on the distribution of the data. . Data are indicated for the whole population and for the sensitivity analysis excluding patients with heart failure for all outcomes. Data are also given by age subgroup (≤75 years or >75 years) for the primary outcome. BP=blood pressure. The p-value reported represents the heterogeneity of the association of BP with each outcome across the BP categories.
